RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study

Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19
Top-line results expected in the coming weeks
Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstrated potent inhibition of Beta and Gamma variants and is expected to be effective against emerging variants, including Delta and Delta Plus
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640)

Related Keywords

South Africa ,Israel ,Switzerland ,Brazil ,Brazilian ,South African ,Redhill Biopharma ,Markl Levitt ,Us National Institute Of Health ,Redhill Biopharma Ltd ,Nasdaq ,Hill Biopharma ,Medical Director ,World Health Organization Ordinal Scale ,Clinical Improvement ,Orphan Drug ,இஸ்ரேல் ,சுவிட்சர்லாந்து ,பிரேசில் ,பிரேசிலியன் ,எங்களுக்கு தேசிய நிறுவனம் ஆஃப் ஆரோக்கியம் ,நாஸ்டாக் ,மருத்துவ இயக்குனர் ,மருத்துவ முன்னேற்றம் ,ஆர்ஃபந் மருந்து ,